Design and pharmacological characterization of selective P2-purinoceptor antagonists

https://doi.org/10.1016/S0165-7208(96)80027-4Get rights and content

Abstract

At least five distinct P2-purinoceptor subtypes have been characterized to date, based on the rank order of potency of several ATP analogues: P2X, P2Y, P2U, P2T and P2Z. However, the characterization of P2-purinoceptor subtypes is hampered by an unavailability of potent, highly selective, competitive antagonists. In the search for selective P2-purinoceptor antagonists, the structure-activity relationships for a series of analogues of pyridoxal-5-phosphate and suramin at P2-purinoceptor subtypes were investigated in our laboratories. Two of these compounds were the subject of a more detailed pharmacological characterization: pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS) and the symmetrical 3′-urea of 8-(benzamido)naphthalene-1,3,5-trisulfonic acid (NF023). The results demonstrate that the two parent compounds, pyridoxal-5-phosphate and suramin, do not differentiate between P2X- and P2Y-purinoceptors. In contrast, PPADS and NF023 were found to be selective antagonists of P2X-purinoceptor-mediated responses in several smooth muscle preparations. In addition, PPADS and NF023 were shown to displace competitively the binding of [3H]α,β-methylene ATP to rabbit and rat bladder membranes, respectively, which indicates that these two compounds act directly on P2X-receptors. PPADS and NF023 were ineffective at P2U-purinoceptors in rat mesenteric arterial bed. P2T-purinoceptor-mediated platelet aggregation was only affected by PPADS in concentrations higher than 100 μM. Suramin and NF023 were inhibitors of ecto-ATPase activity in the same concentration range needed for P2-purinoceptor antagonism. In contrast, PPADS was only very weakly active in inhibiting ecto-ATPase activity. AT 100 μM, PPADS and NF023 did not interact with α1-adrenoceptors, adenosine A1- and A2-, histamine H1- and muscarinic M1-, M2- and M3-receptors.

In conclusion, PPADS and NF023 are specific P2-purinoceptor antagonists showing a high selectivity for the P2X-subtype. These two compounds may prove to be useful starting points in the synthesis of novel, highly potent and selective antagonists at P2-purinoceptor subtypes.

References (64)

  • ZimmermannH.

    Trends Neurosci

    (1994)
  • BurnstockG et al.

    Gen Pharmacol

    (1985)
  • AbbracchioMP et al.

    Pharmac Ther

    (1994)
  • KennedyC et al.

    Trends Pharmacol Sci

    (1995)
  • WebbTE et al.

    FEBS Lett

    (1993)
  • SurprenantA et al.

    Trends Neurosci

    (1995)
  • HumphriesRG et al.

    Trends Pharmacol Sci

    (1995)
  • LambrechtG et al.

    Eur J Pharmacol

    (1992)
  • van RheeAM et al.

    Eur J Pharmacol Mol Pharmacol Sect

    (1994)
  • StrassmannG et al.

    Int J Immunopharmac

    (1994)
  • OesterleR et al.

    Antiviral Res

    (1993)
  • RubioGJ et al.

    Eur J Cancer

    (1995)
  • HouraniSMO et al.

    Gen Pharmacol

    (1989)
  • MallardN et al.

    Eur J Pharmacol

    (1992)
  • HallDA et al.

    Biochem Pharmacol

    (1994)
  • UrbanekE et al.

    Eur J Pharmacol

    (1990)
  • LaytonD et al.

    Biochem Biophys Res Commun

    (1974)
  • TreziseDJ et al.

    Eur J Pharmacol

    (1994)
  • KhakhBS et al.

    Eur J Pharmacol

    (1994)
  • HoyleCHV
  • ChenZP et al.

    J Neuroendocrinol

    (1995)
  • FredholmBB et al.

    Pharmacol Rev

    (1994)
  • DalzielHH et al.

    Pharmacol Rev

    (1994)
  • ZiganshinAU et al.

    Drug Dev Res

    (1994)
  • FiltzTM et al.

    Mol Pharmacol

    (1994)
  • LustigKD et al.
  • ParrCE et al.
  • DubyakGR et al.

    Am J Physiol

    (1993)
  • DubyakGR

    Am J Respir Cell Mol Biol

    (1991)
  • HardenTK et al.

    Annu Rev Pharmacol Toxicol

    (1995)
  • ValeraS et al.

    Nature

    (1994)
  • BrakeAJ et al.

    Julius D. Nature

    (1994)
  • Cited by (0)

    View full text